Rapport Therapeutics
RAPP· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +71.0% in FY2025
Abraham Ceesay, M.B.A. is the CEO of Rapport Therapeutics and was paid $6.3M in FY2025 (Dec), down 36%.
Pay$100 in the stock at the end of FY24 → $171
Executives3
See all- 1Abraham Ceesay, M.B.A.Chief Executive OfficerFY2025
- 2Jeffrey Sevigny, M.D.Chief Medical OfficerFY2025
- 3Troy IgnelziChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allRapport Therapeutics paid its 3 named executives $11.8M in total in FY2025 (Dec). CEO Abraham Ceesay, M.B.A. was paid $6.3M of that.
| Name | |||
|---|---|---|---|
| Abraham Ceesay, M.B.A.Chief Executive Officer | |||
| Jeffrey Sevigny, M.D.Chief Medical Officer | Not disclosed | Not disclosed | |
| Troy IgnelziChief Financial Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Rapport Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board6
See all- Reid Huber, Ph.D.Director · 3 yr on the boardIndependentScience and Technology—Paid as an executive
- Abraham Ceesay, M.B.A.Director · 2 yr on the boardNot independent—Paid as an executive
- John Maraganore, Ph.D.Director · 1 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Raymond Sanchez, M.D.Director · 1 yr on the boardIndependentCompensation, Science and Technology—Paid as an executive
- Robert J. PerezDirector · 1 yr on the boardIndependentCompensation, Nominating and Corporate Governance (Chair)—Paid as an executive
- Wendy B. Young, Ph.D.Director · 1 yr on the boardIndependentScience and Technology (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings4
See all| Proxy statement | DEF 14A | Apr 23, 2026 | FY2025 |
| Annual report | 10-K | Mar 10, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 24, 2025 | FY2024 |
| Annual report | 10-K | Mar 11, 2025 | FY2024 |
